{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:55:52Z","timestamp":1790250952950,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.taap.2016.03.008","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T14:16:19Z","timestamp":1458224179000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of dibenzoylhydrazines"],"prefix":"10.1016","volume":"298","author":[{"given":"Ken-ichi","family":"Miyata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumitsu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2016.03.008_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.taap.2016.03.008_bb0010","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1023\/A:1013358126640","article-title":"Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein","volume":"18","author":"Adachi","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2016.03.008_bb0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0041-008X(96)80035-4","article-title":"Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein","volume":"141","author":"Bain","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2016.03.008_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature02112","article-title":"Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor","volume":"426","author":"Billas","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.taap.2016.03.008_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00498250903331056","article-title":"Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat","volume":"40","author":"Binkhathlan","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.taap.2016.03.008_bb0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1124\/dmd.111.043083","article-title":"Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice","volume":"40","author":"Bundgaard","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.03.008_bb0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0092-8674(86)90595-7","article-title":"Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells","volume":"47","author":"Chen","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.taap.2016.03.008_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2125.2005.02392.x","article-title":"Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression","volume":"60","author":"Chowbay","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.03.008_bb0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/mp900174z","article-title":"Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]\/IC50 and [I2]\/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies","volume":"7","author":"Cook","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.taap.2016.03.008_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/dmd.104.001230","article-title":"The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a\/1b knockout mouse model","volume":"33","author":"Doran","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.03.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s00232-015-9804-y","article-title":"Membrane assays to characterize interaction of drugs with ABCB1","author":"Fekete","year":"2015","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.taap.2016.03.008_bb0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In vitro P-glycoprotein assays to predict the in vitro interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.03.008_bb0065","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1016\/j.bmc.2007.03.040","article-title":"QSAR study on permeability of hydrophobic compounds with artificial membranes","volume":"15","author":"Fujikawa","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.taap.2016.03.008_bb0070","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1365-2125.2002.01691.x","article-title":"MDR1 genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males","volume":"54","author":"Gerloff","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.03.008_bb0075","author":"FDA Guidance"},{"key":"10.1016\/j.taap.2016.03.008_bb0080","author":"EMA Guideline"},{"key":"10.1016\/j.taap.2016.03.008_bb0085","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/jcbfm.2010.36","article-title":"17-\u03b2-Estradiol: a powerful modulator of blood\u2013brain barrier BCRP activity","volume":"30","author":"Hartz","year":"2010","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.taap.2016.03.008_bb0090","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2016.03.008_bb0095","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/jps.23575","article-title":"Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset","volume":"102","author":"Hoshi","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2016.03.008_bb0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1872312811206020134","article-title":"A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier","volume":"6","author":"Kallem","year":"2012","journal-title":"Drug. Metab. Lett."},{"key":"10.1016\/j.taap.2016.03.008_bb0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1584\/jpestics.D13-022","article-title":"Substrate recognition by P-glycoprotein efflux transporters: structure-ATPase activity relationship of diverse chemicals and agrochemicals","volume":"38","author":"Kanaoka","year":"2013","journal-title":"Pestic. Sci."},{"key":"10.1016\/j.taap.2016.03.008_bb0110","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.6137059","article-title":"Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines","volume":"221","author":"Kartner","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.taap.2016.03.008_bb0115","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/jps.20686","article-title":"Kinetic analyses for species differences in P-glycoprotein-mediated drug transport","volume":"95","author":"Katoh","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2016.03.008_bb0120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1067\/mcp.2002.126177","article-title":"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein","volume":"72","author":"Kurata","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1067\/mcp.2003.26","article-title":"Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol","volume":"73","author":"Lija","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1124\/jpet.107.130294","article-title":"Progress in brain penetration evaluation in drug discovery and development","volume":"325","author":"Liu","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0135","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3109\/00498254.2015.1018985","article-title":"Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat","volume":"45","author":"Loureiro","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.taap.2016.03.008_bb0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.toxlet.2014.09.020","article-title":"P-glycoprotein inhibition by the agricultural pesticide propiconazole and its hydroxylated metabolites: implications for pesticide-drug interactions","volume":"232","author":"Mazur","year":"2015","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.taap.2016.03.008_bb0145","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00008571-200111000-00012","article-title":"Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene","volume":"11","author":"Mealey","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.taap.2016.03.008_bb0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1471-4159.2007.04772.x","article-title":"Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood\u2013brain barrier","volume":"103","author":"Milane","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.taap.2016.03.008_bb0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.03.008_bb0160","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s11095-008-9632-1","article-title":"Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions","volume":"25","author":"Muenster","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2016.03.008_bb0165","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11095-007-9374-5","article-title":"Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development","volume":"24","author":"Ohtsuki","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2016.03.008_bb0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s13318-011-0046-9","article-title":"Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer","volume":"36","author":"Patil","year":"2011","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.taap.2016.03.008_bb0175","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0180","first-page":"33","article-title":"Investigating ivermectin hypersensitivity in collies","volume":"80","author":"Pulliam","year":"1985","journal-title":"Vet. Med."},{"key":"10.1016\/j.taap.2016.03.008_bb0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clpt.2005.01.022","article-title":"Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography","volume":"77","author":"Sasongko","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-glycoprotein, a gatekeeper in the blood-brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.taap.2016.03.008_bb0195","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency of the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.taap.2016.03.008_bb0200","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1172\/JCI118214","article-title":"Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporine A","volume":"96","author":"Schinkel","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2016.03.008_bb0205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0090-9556(24)15306-8","article-title":"Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats","volume":"27","author":"Song","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.03.008_bb0210","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.bbamem.2007.04.001","article-title":"Interaction of insecticides with mammalian P-glycoprotein and their effect on its transport function","volume":"1768","author":"Sreeramulu","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2016.03.008_bb0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.110.035774","article-title":"Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats","volume":"39","author":"Sugimoto","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.03.008_bb0220","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s11095-006-0285-7","article-title":"Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1","volume":"23","author":"Takeuchi","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2016.03.008_bb0225","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0022-3565(25)10423-0","article-title":"Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PL1)","volume":"263","author":"Tanigawara","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0230","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2016.03.008_bb0235","series-title":"The Pesticide Manual","first-page":"1074","author":"Tomlin","year":"2009"},{"key":"10.1016\/j.taap.2016.03.008_bb0240","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/jpet.111.184200","volume":"339","author":"Uchida","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0245","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.114.214536","article-title":"Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys","volume":"350","author":"Uchida","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0250","doi-asserted-by":"crossref","first-page":"24248","DOI":"10.1016\/S0021-9258(18)35757-0","article-title":"Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone","volume":"267","author":"Ueda","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2016.03.008_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00210-008-0345-0","article-title":"A novel screening strategy to identify ABCB1 substrates and inhibitors","volume":"379","author":"Von Richter","year":"2009","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.taap.2016.03.008_bb0260","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphism of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2016.03.008_bb0265","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0022-3565(24)38809-3","article-title":"In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results","volume":"296","author":"Yamazaki","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.03.008_bb0270","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0169-409X(02)00170-9","article-title":"In vitro and in vivo models for assessing drug efflux transporter activity","volume":"55","author":"Zhang","year":"2003","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X16300540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X16300540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T20:42:14Z","timestamp":1748810534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X16300540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":54,"alternative-id":["S0041008X16300540"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2016.03.008","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of dibenzoylhydrazines","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2016.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}